RenovaCare Inc. is developing first-of-its-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. Its initial product under development targets the body’s largest organ, the skin. The company’s flagship technology, the CellMist™ System, uses its patented SkinGun™ to spray a liquid suspension of a patient’s stem cells – the CellMist™ Solution – onto wounds.
Company profile
Ticker
RCAR
Exchange
Website
CEO
Harmel S. Rayat
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AMERICAN ALLIANCE CORP, ENTHEOS TECHNOLOGIES INC, Janus Resources, Inc., WHATSONLINE COM INC
SEC CIK
Corporate docs
IRS number
980170247
RCAR stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
9 Jan 23
15-15D
Suspension of duty to report
30 Dec 22
POS AM
Prospectus update (post-effective amendment)
30 Dec 22
AW
Withdrawal of amendment
30 Dec 22
S-1/A
IPO registration (amended)
30 Dec 22
S-8 POS
Registration of securities for employees (post-effective amendment)
30 Dec 22
10-Q
2022 Q3
Quarterly report
18 Nov 22
NT 10-Q
Notice of late quarterly filing
14 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
Latest ownership filings
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 100.74 k | 100.74 k | 100.74 k | 100.74 k | 100.74 k | 100.74 k |
Cash burn (monthly) | 47.74 k | 276.75 k | 625.79 k | 652.92 k | 49.41 k | 343.84 k |
Cash used (since last report) | 900.08 k | 5.22 mm | 11.80 mm | 12.31 mm | 931.50 k | 6.48 mm |
Cash remaining | -799.34 k | -5.12 mm | -11.70 mm | -12.21 mm | -830.76 k | -6.38 mm |
Runway (months of cash) | -16.7 | -18.5 | -18.7 | -18.7 | -16.8 | -18.6 |
Institutional ownership, Q2 2022
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 5.00 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Captrust Financial Advisors | 5.00 k | $0.00 |